Skip to main content
Premium Trial:

Request an Annual Quote

Enzymatics Buys ArcherDx for up to $50M

NEW YORK (GenomeWeb News) – Enzymatics today announced it has bought ArcherDx, a developer of kits and software solutions for next-generation sequencing, for up to $50 million.

The deal, consisting of cash, equity, and potential milestones, provides Beverly, Mass.-based Enzymatics with genomics capabilities that complement its Enzymatics Supply Chain Solutions and Enzymatics Reagents groups, it said. The acquisition, the company added, also expands the new Enzymatics Diagnostics groups with technology, kits, and analytical solutions for hospitals, research institutions, and other diagnostic providers for the rapid and cost-effective assessment of genetic biomarkers.

In conjunction with the transaction, ArcherDx Co-founder and CEO Jason Myers is joining Enzymatics as chief scientific officer. ArcherDx is based in Boulder, Colo.

"An unprecedented growth in genomics for healthcare is fueling greater demand for faster, more accurate, and more cost effective sequencing applications," Enzymatics' President and CEO Jon DiVincenzo said in a statement. "We are seeing double-digit growth in the placement of new sequencers every year and broad adoption of genomic technologies across clinical communities. Enzymatics, which already supplies reagents and kits to approximately 80 percent of the NGS industry, together with ArcherDx, will bring novel sequencing applications more directly to clinical researchers."

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.